Scinai Immunotherapeutics (SCNI) Net Margin (2024 - 2026)

Scinai Immunotherapeutics has disclosed Net Margin across 3 years of filings, most recently posting 466.52% for Q2 2026.

• In Q2 2026, Net Margin rose 70728.0% year-over-year to 466.52%; the TTM figure through Jun 2026 stood at 486.41% (down 87255.0% YoY), while the FY2025 annual figure was 407.91%, up 90485.0% from the prior year.
• Net Margin came in at 466.52% for Q2 2026 at Scinai Immunotherapeutics, up from 504.5% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 6223.21% in Q3 2024 to a low of 1173.8% in Q2 2025.
• Average Net Margin over 3 years is 452.05%, with a median of 485.51% recorded in 2026.
• The largest YoY upside for Net Margin was 70728 bps in 2026 against a maximum downside of 23692 bps in 2026.
• Over 3 years, Net Margin stood at 1098.54% in 2024, then decreased by 7 bps to 1173.8% in 2025, then surged by 60 bps to 466.52% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 466.52% in Q2 2026, 504.5% in Q1 2026, and 1173.8% in Q2 2025.